Johnson & Johnson Secures Tariff Exemptions for U.S. Drug Price Cuts
Johnson & Johnson secured U.S. tariff exemptions in exchange for cutting prices on its medicines through TrumpRx.gov and expanding Medicaid coverage at developed-nation rates. Industry plans to raise prices on 350 branded drugs in 2026 could offset Johnson & Johnson's tariff-driven margin relief.
Related News
NBTX
Nanobiotix Halts Trading to Finalize €75 M Follow-On Offering Pricing
NBTX•
AVGO
Nvidia Predicts $91B Q3 Sales, Boosts Dividend and $80B Buyback; Broadcom Poised for AI Inference Growth
AVGO•
WMT
Walmart Set for Q1 EPS of $0.66 on $175B Revenue; Value Outlook Tempered
WMT•
NVDA
Nvidia posts $81.6bn Q1 revenue, raises dividend 25-fold and authorizes $80bn buyback
NVDA•
BA
NTSB: Boeing Extended MD-11 Inspection Interval 47% Before Deadly UPS Crash
BA•
Sources
BBDGP